PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

NCT03149549 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

99

Enrollment

INDUSTRY

Sponsor class

Stopped Covid Pandemic; Business Decision to separate Phase 2 to new study

Conditions

Solid Tumor, Adult
Breast Cancer
Non Small Cell Lung Cancer
Head and Neck Cancer
Ovarian Cancer

Interventions

DRUG: CX-2009

Sponsor

CytomX Therapeutics